Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 12

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 12
---
9,328,113 shares of common stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity Incentive Plan; |

| • |     | 12,129,635 shares of common stock issuable upon the exercise of warrants outstanding at a weighted exercise price of $4.69 per share; |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Biosciences, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

4

RISK FACTORS SUMMARY OF RISK FACTORS The following is a summary of the principal risks and uncertainties that could materially adversely affect our business, results of operations, financial condition, cash flows, prospects and/or the price of our outstanding securities and make an investment in our securities speculative or risky. You should read this summary together with the more detailed description of each risk factor contained below.

| • |     | We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability. |

| • |     | We may need substantial additional funding to allow us to support through clinical development and commercial launch, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. |

| • |     | Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. |

| • |     | We are a clinical stage biopharmaceutical company and have a limited operating history upon which to base an investment decision. |

| • |     | We will face intense competition and may not be able to compete successfully. |

| • |     | We may incur substantial product liability or indemnification claims relating to the use of our product candidates |

| • |     | Our product candidates are at an early stage of development and may not be successfully developed or commercialized. |

| • |     | Any product candidates we advance into